Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Conference, Product/Service, Trade Show

Exactech Expands Vantage® Ankle Portfolio with Clearance of Advanced Activit-Etm Polyethylene


Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced 510(k) clearance for its Activit-Etm polyethylene for the Vantage® Total Ankle System. This announcement comes on the heels of the Activit-E clearance for the Truliant® Knee System, which was announced last month.

"We're excited to bring Activit-E to the ankle portfolio. This advanced material gives us the best-wear performance we've tested combined with higher fracture toughness than other highly crosslinked vitamin E polyethylenes.1 Both are important factors when designing implants for a very active patient population," said Exactech's Director of Engineering, Foot and Ankle, Matt Hamilton.

Activit-E is a next-generation highly crosslinked polyethylene with vitamin E antioxidant stabilization. Its unique manufacturing process replaces gamma irradiation crosslinking with peroxide crosslinking and adds vitamin E to provide strength, flexibility, toughness, and oxidative stability. This technology also ensures patients will be able to access the clinical benefits of highly crosslinked polyethylene despite the anticipated shortage of gamma radiation for crosslinking.

"Our new polyethylene brings an optimized balance of material strength and toughness through its ability to maintain active oxidative resistance and long-term, high performance," said Devan Carter, Exactech's foot and ankle marketing director. "We look forward to seeing how Activit-E, coupled with our data-driven total ankle system1, can help patients nationwide get back to the activities they love."

Activit-E was developed by Orhun Muratoglu, Ph.D., director of the Harris Orthopaedic Laboratory at Massachusetts General Hospital in Boston, and his team, including Ebru Oral, Ph.D, director of Biomaterials Research. Muratoglu and his team invented the first generation highly crosslinked polyethylene, and Muratoglu, together with Oral, pioneered Vitamin E stabilization in highly crosslinked polyethylenes that are in clinical use worldwide.

Pilot launch for Activit-E is expected in the first quarter of 2024, and attendees at this week's American Orthopaedic Foot and Ankle Society (AOFAS) Annual Meeting can get an exclusive look at this new technology at Exactech's booth (#301). Learn more about Exactech's AOFAS activities at http://www.exac.com/aofas.

About Exactech

Exactech is a global medical device company that develops and markets orthopaedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit www.exac.com for more information and connect with us on LinkedIn, VuMedi, YouTube, Twitter and Instagram. With Exactech by your side, you've got EXACTLY what you need.

References:

  1. Data on file at Exactech, Inc.

These press releases may also interest you

at 02:38
Today, Tuesday 14 May, starting at 13:30 CEST, ASSA ABLOY hosts its Capital Markets Day in Prague, Czech Republic, where Nico Delvaux, President & CEO and Erik Pieder, CFO, will provide an update on ASSA ABLOY's strategy and direction. This will...

at 02:38
Allied Market Research published a report, titled, "Biometric Payment Market by Type (Contact-Based, Contactless, Hybrid), Biometric Mode (Fingerprint Recognition, Facial Recognition, Voice Recognition, Iris Scans, Others), and...

at 02:26
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, welcomes a new hospital performing the RefluxStoptm procedure in Italy, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone. In late...

at 02:25
Hygiene and health company Essity is investing in a new global center for research and development, in Alsace, France, dedicated to tissue hygiene products. The state-of-the-art facility will focus on tissue to meet the evolving demands of branded...

at 02:20
Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to...

at 02:00
Valcare Medical, Inc., a leading innovator in transcatheter-based mitral solutions, announces the successful completion of the first two enrollments in the AMEND TS European pilot study.  Dr. Bruno Melica and the team from Vila Nova de Gaia Hospital,...



News published on and distributed by: